PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Salbutamol - Asthma
PAD Profile : Salbutamol - Asthma
Keywords :
severe asthma, severe respiratory disease, acute asthma, reversible airways obstruction
Traffic Light Status
Status 1 of 3.
Status :
Red
Important
Formulations :
- Injection
Important Information :
Unlicensed use in under 12 years of age.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 3.
Status :
Green
Formulations :
- Nebules
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Status 3 of 3.
Guidelines
No guidelines returned.
Other Drugs
- Fostair NEXThaler (beclometasone and formoterol)
- Montelukast
- Theophylline
- Easyhaler (Salbutamol)
- Clenil Modulite (beclometasone)
- Easyhaler (Beclometasone)
- Easyhaler (Budesonide)
- Fostair (Beclometasone and formoterol)
- Budelin Novolizer (budesonide)
- Dupilumab
- Airflusal (Salmeterol/Fluticasone) MDI
- Aerivio Spiromax (Fluticasone/Salmeterol) DPI
- Ventolin Accuhaler (salbutamol)
- Sereflo Ciphaler (Salmeterol / Fluticasone) DPI
- Campona Airmaster (Salmeterol / Fluticasone) DPI
- Terbutaline sulphate
- Budesonide
- Salamol Easi-Breathe
Other Indications
- Asthma
- Asthma
- Delay of premature labour
- Respiratory disease indications
- Respiratory disease indications
- Asthma
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
06 November 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.
Associated BNF Codes
03. Respiratory System
03.01.01. Adrenoceptor agonists